Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2162 · · 10 pages · English
Summary by 6ix AI
It includes information on the company's authorized and registered share capital, confirming a total at the end of the month. The report also confirms the sufficiency of the public float for the company's shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Keymed Biosciences, Inc. on 6ix
Earlier from Keymed Biosciences
- 2026 Interim report
- Keymed Biosciences Announces 2026 H1 Results and Business Updates
- Keymed Biosciences Announces 2025 Annual Results and Business Updates
- Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum
- Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine
Later from Keymed Biosciences
All Keymed Biosciences news releasesFollow Keymed Biosciences into a list and get an email when it puts out news.
Follow Keymed Biosciences